Old Web
English
Sign In
Acemap
>
Paper
>
TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL
TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL
2021
Mikhail Kosiborod
Meena Bhatta
Melanie J. Davies
John E. Deanfield
Tim Garvey
Usman Khalid
Robert F. Kushner
Domenica M. Rubino
Niels Zeuthen
Subodh Verma
Keywords:
Semaglutide
Medicine
cardiometabolic risk
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]